Pfizer sees blockbuster potential for low-profile PARP drug Talzenna after prostate cancer combo win aliu Tue, 10/04/2022 – 10:03 More: Pfizer sees blockbuster potential for low-profile PARP drug Talzenna after prostate cancer combo win Source: fierce
read moreIn ‘skinny’ label fight between Teva and GSK, Supreme Court asks Biden admin for help fkansteiner Tue, 10/04/2022 – 09:35 More: In 'skinny' label fight between Teva and GSK, Supreme Court asks Biden admin for help Source: fierce
read moreTreatment involves adult patients with severe alopecia areata More: Eli Lilly receives marketing authorisation for baricitinib Source: News
read moreUniversity of Lincoln and the University of Sheffield are researching how DNA could be repaired More: ‘Junk’ DNA may hold the key to neurological disorders Source: News
read moreAs Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win aliu Mon, 10/03/2022 – 11:52 More: As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win Source: fierce
read moreAmid scrutiny around Europe’s vaccine purchase, Pfizer CEO Albert Bourla pulls out of committee hearing zbecker Mon, 10/03/2022 – 11:23 More: Amid scrutiny around Europe's vaccine purchase, Pfizer CEO Albert Bourla pulls out of committee hearing Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals